Alfa Cytology has announced tumor models customization service for pancreatic cancer research. Alfa Cytology, a biotech company specializing in cancer research, has recently unveiled the service on pancreatic cancer tumor model customization to dig into the generation and ...Learn More

Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. The services tend ...Learn More

Alfa Cytology announced its pancreatic cancer research services for anticancer therapy in the early preclinical stages. Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful ...Learn More

Alfa Cytology has announced its molecular biology services for TME research. Alfa Cytology, a specialized biotechnology company headquartered in the United States, focusing on tumor microenvironment (TME), has announced its molecular biology services for TME research. The ...Learn More

The development of monoclonal antibodies (mAbs) has completely transformed the field of medicine, providing targeted antidotes against a wide range of diseases, including cancer, autoimmune and infectious diseases. These therapeutic antibodies aim to specifically target antigens ...Learn More